Axcan shares fall C$1.03, or 6.9 percent, at C$13.87 at midday after dropping as low as C$13.06 earlier in the session."Although we are disappointed by these results, we will continue to thoroughly analyze the data from this study.
Based on current insights, we do not think that there is enough evidence of efficacy of Itopride, even when combining the results of both the International Phase III study reported earlier this year and the Phase II study conducted in Germany, to support a path for development of Itopride for Functional Dyspepsia.
As a consequence, we have decided to suspend further development of Itopride in this indication.
Comment Preview